Research Article

High-Risk Indicators of Renal Involvement in Primary Sjogren’s Syndrome: A Clinical Study of 1002 Cases

Jing Luo,1 Yu-Wei Huo,2 Jian-Wu Wang,2 and Hui Guo2,3

1Division of Rheumatology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
2Division of Nephrology, Department of Medicine, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
3Division of Nephrology, Department of Medicine, Shenzhen University General Hospital, Shenzhen, Guangdong 518005, China

Correspondence should be addressed to Hui Guo; ghty966@hotmail.com

Received 4 September 2018; Revised 26 November 2018; Accepted 9 January 2019; Published 17 February 2019

Guest Editor: Long Shen

Copyright © 2019 Jing Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. A retrospective analysis of clinical characteristics and immunological manifestations of primary Sjogren’s syndrome (pSS) patients with or without renal involvement was conducted in order to elucidate the potential risk factors of renal damage in pSS and evaluate the condition.

Methods. A total of 1002 patients, who fulfilled the 2002 classification criteria for pSS from the Second Affiliated Hospital of Shanxi Medical University, were enrolled in the cross-sectional study. Clinical, immunological, and histological characteristics were compared between pSS patients with and without renal involvement, and potential risk factors of renal involvements in pSS patients were examined by multivariate analysis.

Results. Among these pSS patients, there were 162 cases (16.17%) with and 840 cases (83.83%) without renal damage. Serious edema of both lower limbs, interstitial nephritis, and renal tubular acidosis were found in the pSS with renal damage group. Compared with simple pSS patients, the levels of creatinine, cystatin C, and alpha-1-microglobulin (α1-MG) in the pSS with renal damage group were significantly increased. The difference between the two groups was statistically significant (P<0.05). The AUC of the combination of creatinine and α1-MG and creatinine, α1-MG, and creatinine was statistically larger than that of creatinine, and the biomarker of the biggest AUC is the combination of creatinine and α1-MG.

Conclusion. The main clinical manifestations of pSS with renal damage were edema of the lower limbs, interstitial nephritis, and renal tubular acidosis. Creatinine and α1-MG are effective indicators for renal function in pSS, which may provide a better understanding for clinical decision-making.

1. Introduction

Sjogren’s syndrome (SS) is a chronic progressive autoimmune disorder characterized by lymphocytic infiltration of the exocrine glands, which affects the salivary and lacrimal glands, presenting dryness of the mouth and eyes. The majority of infiltrating mononuclear cells are CD4+ T cells [1]. Some patients may present diverse extraglandular impairment such as that in the lungs, kidneys, nervous system, and skin affected by this disorder [2]. The predominant serologic findings of pSS are positive anti-nuclear antibodies (ANA), anti-SSA antibodies, and anti-SSB antibodies. Renal involvement is easily ignored by the physicians because the clinical symptoms are often insidious. Growing evidence suggests that patients with pSS may have greater renal injury risk than the general population and the most common renal disease in SS is tubulointerstitial nephritis, responsible for renal tubular acidosis in 20% [3]. However, it is still challenging to diagnose renal involvement in pSS patients.

In the present study, we described the clinical presentation and serologic findings of 840 patients with pSS without renal involvement and 162 patients with renal involvement. We also analyzed whether biochemical markers were useful in identifying renal disease in pSS patients to guide further clinical work.
|                                | Without renal involvement | With renal involvement | P value |
|--------------------------------|---------------------------|------------------------|---------|
| Seroperitoneum                 | 0                         | 6 (3.7%)               | 0.000   |
| Dizziness                      | 12 (1.4%)                 | 8 (4.9%)               | 0.003   |
| Palpitate                      | 14 (1.7%)                 | 6 (3.7%)               | 0.090   |
| Breathe hard                   | 26 (3.1%)                 | 9 (5.6%)               | 0.118   |
| Digestive tract symptoms       | 19 (2.3%)                 | 31 (19.1%)             | 0.000   |
| Respiratory system symptoms    | 30 (3.6%)                 | 15 (9.3%)              | 0.001   |
| Congestion of throat           | 1 (0.1%)                  | 10 (6.2%)              | 0.000   |
| Bilateral pleural effusion     | 0                         | 3 (1.9%)               | 0.000   |
| Lipsotrichia                   | 53 (6.3%)                 | 4 (2.5%)               | 0.053   |
| Dry cough                      | 4 (0.5%)                  | 1 (0.6%)               | 0.815   |
| Edema in the face              | 5 (0.6%)                  | 14 (8.6%)              | 0.000   |
| Edema of both lower limbs      | 13 (1.5%)                 | 42 (25.9%)             | 0.000   |
| Hypourocrinia                  | 0                         | 4 (2.5%)               | 0.000   |
| Frequent micturition           | 8 (1.0%)                  | 10 (6.2%)              | 0.000   |
| Urgency of urine               | 8 (1.0%)                  | 7 (4.3%)               | 0.000   |
| Odynuria                       | 3 (0.4%)                  | 4 (2.5%)               | 0.003   |
| Rampant caries                 | 187 (22.3%)               | 34 (21%)               | 0.720   |
| Erythema                       | 149 (17.7%)               | 23 (14.2%)             | 0.274   |
| Weak                            | 119 (14.2%)               | 50 (30.9%)             | 0.000   |
| Poor appetite                   | 9 (1.0%)                  | 25 (15.4%)             | 0.000   |
| Dry mouth                      | 669 (79.6%)               | 129 (79.6%)            | 0.997   |
| Xerophthalmia                  | 457 (54.4%)               | 94 (58%)               | 0.396   |
| Arthralgia                      | 493 (58.7%)               | 68 (42%)               | 0.000   |
| Fever                           | 149 (17.7%)               | 28 (17.3%)             | 0.890   |
| Reynolds                        | 33 (3.9%)                 | 9 (5.6%)               | 0.344   |
| Dental ulcer                    | 69 (8.2%)                 | 16 (9.9%)              | 0.487   |
| Courpature                      | 1 (0.1%)                  | 1 (0.6%)               | 0.193   |
| Hematuria                       | 0                         | 1 (0.6%)               | 0.023   |
| Polydipsia                      | 1 (0.1%)                  | 2 (1.2%)               | 0.021   |
| Diuresis                        | 1 (0.1%)                  | 2 (1.2%)               | 0.021   |
| Nocturia                        | 2 (0.2%)                  | 17 (18.5%)             | 0.000   |
| Parotid swelling and pain      | 29 (3.5%)                 | 3 (1.9%)               | 0.289   |
| Anti-scl-70                     | 0                         | 2 (1.2%)               | 0.001   |
| Anti-Jo-1                       | 0                         | 2 (1.2%)               | 0.001   |
| pANCA                           | 17 (2%)                   | 4 (2.5%)               | 0.717   |
| cANCA                           | 3 (0.4%)                  | 1 (0.6%)               | 0.631   |
| RF                              | 144 (17.1%)               | 44 (27.2%)             | 0.003   |
| Anti-ENA                        | 169 (20.1%)               | 59 (36.4%)             | 0.000   |
| Anti-ds DNA                     | 18 (2.1%)                 | 3 (1.9%)               | 0.813   |
| Anti-SSA                        | 579 (68.9%)               | 80 (49.4%)             | 0.000   |
| Anti-SSB                        | 54 (6.4%)                 | 19 (11.7%)             | 0.017   |
| Anti-Sm                         | 4 (0.5%)                  | 4 (2.5%)               | 0.009   |
| Anti-RNP                        | 87 (10.4%)                | 15 (9.3%)              | 0.672   |
Table 2: Demographic, clinical, histological, immunological and inflammatory features of primary Sjogren’s syndrome with or without renal involvement.

|                     | Without renal involvement | With renal involvement | P value |
|---------------------|---------------------------|------------------------|---------|
| Age                 | 49.46 ± 13.36             | 49.94 ± 15.39          | 0.713   |
| Mouth disease       | 69.44 ± 83.05             | 56.76 ± 91.78          | 0.082   |
| White blood cell    | 6.15 ± 3.035              | 6.34 ± 3.03            | 0.485   |
| RBC                 | 4.08 ± 0.61               | 3.66 ± 0.87            | 0.000   |
| Hb                  | 122.61 ± 26.56            | 109.75 ± 24.94         | 0.000   |
| Platelet            | 209.61 ± 101.51           | 214.66 ± 100.74        | 0.562   |
| Monocyte            | 0.43 ± 0.25               | 0.45 ± 0.42            | 0.402   |
| Eosinophil          | 0.11 ± 0.17               | 0.13 ± 0.16            | 0.181   |
| Lymphocyte%         | 28.73 ± 11.31             | 28.57 ± 11.82          | 0.872   |
| Lymphocyte          | 1.66 ± 1.64               | 1.66 ± 0.84            | 0.973   |
| Monocyte%           | 7.44 ± 3.85               | 6.77 ± 2.49            | 0.005   |
| Eosinophil%         | 1.86 ± 2.35               | 1.97 ± 2.15            | 0.568   |
| Urine RBC           | 5.79 ± 38.71              | 26.95 ± 100.88         | 0.009   |
| Urine WBC           | 18.30 ± 57.64             | 11.60 ± 39.55          | 0.071   |
| Urine pH            | 6.34 ± 0.78               | 6.28 ± 1.00            | 0.463   |
| Proportion          | 1.02 ± 0.01               | 1.02 ± 0.01            | 0.074   |
| ALT                 | 32.81 ± 35.05             | 30.9 ± 77.11           | 0.618   |
| AST                 | 32.66 ± 33.19             | 35.79 ± 80.43          | 0.626   |
| AST/ALT             | 1.18 ± 0.56               | 1.28 ± 0.47            | 0.039   |
| Total bilirubin     | 14.26 ± 14.24             | 13.04 ± 33.11          | 0.445   |
| Direct bilirubin    | 4.19 ± 7.15               | 4.53 ± 19.00           | 0.822   |
| Indirect bilirubin  | 10.06 ± 8.34              | 8.77 ± 14.62           | 0.121   |
| Prealbumin          | 234.65 ± 56.94            | 262.90 ± 66.57         | 0.000   |
| Total protein       | 71.10 ± 10.40             | 68.16 ± 11.80          | 0.000   |
| Albumin             | 37.28 ± 5.51              | 34.475 ± 6.87          | 0.004   |
| Globulin            | 33.45 ± 9.10              | 33.70 ± 9.48           | 0.000   |
| Albumin/globulin    | 1.19 ± 0.35               | 1.10 ± 0.36            | 0.001   |
| Alkaline phosphatase| 99.26 ± 99.52             | 102.35 ± 68.45         | 0.687   |
| Glutamyl transpeptidase| 53.52 ± 102.20           | 37.64 ± 69.78          | 0.015   |
| Total bile acid     | 9.73 ± 20.71              | 10.21 ± 37.32          | 0.815   |
| 5-Nucleoglykase     | 8.45 ± 14.37              | 6.73 ± 10.15           | 0.147   |
| Adenosine deaminase | 19.01 ± 11.93             | 18.84 ± 9.07           | 0.858   |
| Blood glucose (4.2-6.1) | 5.31 ± 1.57             | 5.18 ± 1.06            | 0.332   |
| Fructosamine        | 1.83 ± 0.65               | 1.81 ± 0.56            | 0.633   |
| Urea nitrogen       | 4.50 ± 1.76               | 8.43 ± 6.62            | 0.000   |
| Creatinine          | 55.70 ± 14.32             | 150.82 ± 150.41        | 0.000   |
| CO₂ CP              | 25.08 ± 2.84              | 22.54 ± 4.60           | 0.000   |
| Cystatin C          | 1.09 ± 0.36               | 2.04 ± 1.38            | 0.000   |
| α₁-MG (10-30 ng/L)  | 20.89 ± 7.95              | 34.04 ± 15.93          | 0.000   |
| β₂-MG (0.97-2.64 ng/L) | 2.81 ± 5.19              | 6.02 ± 5.64            | 0.000   |
| Uric acid (90-420 μmol/L) | 246.66 ± 78.60          | 292.70 ± 115.11        | 0.000   |
| Complement-C1q (159-233 mg/L) | 198.06 ± 14.16           | 199.79 ± 15.72         | 0.164   |
2. Materials and Methods

2.1. Methods

2.1.1. Study Population and Clinical Data. A total of 1002 patients who fulfilled the 2002 classification criteria [4] for pSS from the Rheumatology Department of the Second Affiliated Hospital of Shanxi Medical University between September 2013 and September 2017 were enrolled in this study. The study was approved by the Ethical Committee of the Second Affiliated Hospital of Shanxi Medical University (approval # 2016KY007). The study design conformed to the current National Health and Family Planning Commission of China ethical standards, with written informed consent provided by all patients.

Sjogren’s syndrome without other autoimmune diseases is called pSS. pSS patients were diagnosed with clinical data as oral and ocular dryness, constitutional symptoms, vasculitis, and joint, skin, pulmonary, kidney, gastrointestinal tract, and endocrine involvement. The clinical observation items

| Without renal involvement | With renal involvement | P value |
|---------------------------|------------------------|--------|
| K (3.5-5.5 mmol/L)        | 3.91 ± 0.41            | 3.93 ± 0.63 | 0.631 |
| Na (137-147 mmol/L)       | 139.50 ± 3.47          | 139.31 ± 4.08 | 0.579 |
| Cl (99-110 mmol/L)        | 105.34 ± 3.66          | 107.38 ± 5.36 | 0.000 |
| Ca (2.08-2.6 mmol/L)      | 2.24 ± 0.14            | 2.19 ± 0.18 | 0.000 |
| P (0.83-1.48 mmol/L)      | 1.23 ± 0.50            | 1.26 ± 0.30 | 0.465 |
| Mg (0.7-1.1 mmol/L)       | 0.91 ± 0.10            | 0.93 ± 0.12 | 0.145 |
| Fe                        | 14.07 ± 6.61           | 13.31 ± 7.20 | 0.190 |
| CK                        | 66.41 ± 124.01         | 82.60 ± 192.51 | 0.304 |
| CK-MB                     | 9.39 ± 8.96            | 8.90 ± 6.54 | 0.502 |
| LDH                       | 221.41 ± 168.21        | 233.16 ± 201.45 | 0.432 |
| HBD                       | 173.22 ± 141.13        | 180.03 ± 136.94 | 0.572 |
| Total cholesterol         | 4.55 ± 1.25            | 4.53 ± 1.82 | 0.883 |
| Triglyceride              | 1.90 ± 2.05            | 2.18 ± 2.36 | 0.156 |
| HDL                       | 1.21 ± 0.43            | 1.14 ± 0.37 | 0.054 |
| LDL                       | 2.66 ± 0.84            | 2.61 ± 1.25 | 0.607 |
| Apolipoprotein-A<sub>1</sub> | 1.30 ± 0.39         | 1.23 ± 0.32 | 0.033 |
| Apolipoprotein-B<sub>100</sub> | 0.84 ± 0.23       | 0.90 ± 0.38 | 0.581 |
| Apolipoprotein-E          | 38.84 ± 12.74          | 40.23 ± 22.27 | 0.443 |
| Lipoprotein-α             | 18.41 ± 18.30          | 23.19 ± 21.88 | 0.010 |
| HDL/cholesterol           | 27.13 ± 7.68           | 21.51 ± 9.02 | 0.615 |
| Acid phosphatase          | 4.29 ± 2.76            | 5.15 ± 2.82 | 0.000 |
| ESR                       | 38.29 ± 33.68          | 54.84 ± 36.36 | 0.000 |
| CRP                       | 10.35 ± 20.25          | 10.62 ± 20.50 | 0.877 |
| Complement-C<sub>3</sub>  | 1.01 ± 0.24            | 0.95 ± 0.22 | 0.004 |
| Complement-C<sub>4</sub>  | 0.23 ± 0.25            | 0.25 ± 0.14 | 0.370 |
| PTH                       | 38.52 ± 17.82          | 220.28 ± 307.65 | 0.032 |
| CA19-9 (<35 KU/L)         | 12.45 ± 16.20          | 13.12 ± 15.81 | 0.624 |
| CEA < 5 ng/L              | 2.17 ± 1.55            | 2.33 ± 0.99 | 0.021 |
| AFP < 20 ng/L             | 2.81 ± 2.06            | 2.73 ± 2.36 | 0.655 |
| IgG                       | 14.84 ± 6.78           | 14.76 ± 7.59 | 0.891 |
| IgA                       | 2.86 ± 1.46            | 3.02 ± 1.31 | 0.192 |
| IgM                       | 1.64 ± 1.39            | 1.37 ± 0.75 | 0.000 |
| Light chain quantitative κ (5.74-12.8 g/L) | 7.87 ± 26.02 | 11.96 ± 8.27 | 0.283 |
| Light chain quantitative L (2.69-6.38 g/L) | 2.08 ± 3.87 | 86.07 ± 565.90 | 0.294 |
included age, gender, course of disease, glandular symptoms (xerostomia and xerophthalmia), and extraglandular symptoms (arthritis, erythema, edema, and digestive, respiratory, and renal involvement). Routine laboratory examinations were performed including routine blood test, routine urine test, liver function examination, naphric function examination, erythrocyte sedimentation rate (ESR), cystatin C, and α₁-MG. Biochemical tests were performed using standard methods in a Beckman Coulter AU 5800 chemistry analyzer, and serum creatinine measurements were used by an IDMS-traceable method. Immunologic examinations which included anti-SSA, anti-SSB, and rheumatoid factors were performed using an immunoblotting method.

2.1.2. Assessment of Renal System Involvement. We identified those with clinically significant renal involvement.

Clinically significant renal involvement in pSS, either interstitial nephritis or GN, was defined by one or more of the following criteria:

(1) Renal tubular acidosis (RTA). Subtypes of RTA were determined as follows [5]: RTA type I (distal): hyperchloremic acidosis with a minimum urine pH ≥ 5.3 and low/normal plasma potassium (< 5.5 mmol/L), based on reduced H+ secretion in the distal tubule; RTA type II (proximal): hyperchloremic acidosis with a minimum urine pH < 5.3 and low/normal plasma potassium (< 5.5 mmol/L), based on reduced HCO3− reabsorption in the proximal tubule; and RTA type IV: hyperchloremic acidosis with a minimum urine pH < 5.3 and high plasma potassium (≥ 5.5 mmol/L), based on reduced H+ and K+ excretion in the distal tubule

(2) Kidney biopsy demonstrating histologic features compatible with glomerulonephritis, interstitial nephritis, or both

(3) Fanconi syndrome not associated with any known cause

(4) Elevated serum creatinine levels

(5) Proteinuria > 500 mg/24 hours

(6) Active urine sediment (> 3 red blood cells per high-power field or red blood cell casts)

2.2. Statistical Analysis. Normally distributed variables were expressed as mean ± standard deviation (SD) and compared using independent samples t-test or one-way ANOVA. Nonparametric variables were expressed as medians and interquartile range (IQR) and compared using Mann–Whitney U or Kruskal–Wallis test. Categorical variables were compared using a χ²-test. To examine correlations between risk factors and renal involvement, univariate analyses were used, firstly based on biological plausibility and literature review. Variables with P < 0.05 in univariate analysis were then included in a multivariate analysis using logistic regression. Statistical significance was set at P < 0.05. All analyses were conducted using SPSS 22.0 statistical software packages.

3. Results

3.1. The Characteristics of pSS Patients with or without Renal Involvement. Demographic, clinical, histological, immunological, inflammatory feature, and outcome measure data were presented in Tables 1 and 2, collected from -162 pSS patients with and 840 without renal involvement. The female to male ratio in pSS patients is 779 : 61 (92.7%). Most patients presented to the hospital at 49 years old for the first interview, and an average disease course was approximately 5 years. Compared with pSS patients without renal involvement, those with renal involvement showed much higher

| Table 3: Pathological types of kidney in 12 PSS patients with renal involvement. |
| Pathological type | Case |
|-------------------|------|
| Mild mesangial proliferative nephritis with subacute tubulointerstitial nephropathy | 1 |
| Stage III glomerulosclerosis of nodular sclerosing diabetes mellitus | 1 |
| Mild mesangial hyperplasia | 1 |
| Atypical membranous nephropathy | 1 |
| Changes of renal tubular injury during convalescence | 1 |
| Focal proliferative sclerosing glomerulonephritis | 1 |
| Focal proliferative IgA nephropathy | 1 |
| Subacute tubulointerstitial nephropathy | 1 |
| Mild mesangial proliferative nephritis with subacute tubulointerstitial nephropathy | 1 |
| Stages I-II membranous nephropathy | 1 |
| Chronic interstitial renal damage | 1 |
| Atypical membranous nephropathy with multiple crescents and acute tubular injury | 1 |

| Table 4: Features of renal involvement in primary Sjogren’s syndrome patients. |
| Renal involvement | Numbers | Percentage (%) |
|-------------------|--------|----------------|
| Edema in the face | 14 | 8.6 |
| Edema of both lower limbs | 42 | 25.9 |
| Hypourcrocina | 4 | 2.5 |
| Frequent miciturition | 10 | 6.2 |
| Urgency of urine | 7 | 4.3 |
| Hematuria | 1 | 0.6 |
| Diuresis | 2 | 1.2 |
| Nocturia | 17 | 18.5 |
| Interstitial nephritis | 6 | 3.7 |
| Renal tubular acidosis | 12 | 7.4 |

Receiver operating characteristic (ROC) curves were plotted to explore the significance of multiple biomarkers for renal function in pSS. The differences among the areas under the receiver operating characteristic (ROC) curves (AUC) were calculated by MedCalc Software (version 15.2.0; MedCalc Software, Belgium).
levels of prealbumin, anti-scl-70, rheumatoid factor (RF), anti-extractable nuclear antigen (anti-ENA), anti-SSA, anti-SSB, anti-SM, globulin, urea nitrogen, cystatin C, creatinine, α1-MG, serum β2 microglobulin (β2-MG), uric acid, Cl, lipoprotein-a, acid phosphatase, ESR, parathyroid hormone (PTH), and carcinoembryonic antigen (CEA), but reduced level of monocyte, anti-SSA, total protein, albumin, carbon dioxide combining power (CO2CP), Ca, red blood cell (RBC), hemoglobin (Hb), apolipoprotein-A1, immunoglobulin M (IgM), and complement-C3 \((P < 0.05)\). Comparison of the two groups of clinical manifestations is shown in Tables 1 and 2.

3.2. The Characteristics of Renal Involvement in Primary Sjogren’s Syndrome Patients. The SS patients with renal involvements showed glandular symptoms (xerostomia and xerophthalmia) and extraglandular symptoms (arthritis, erythema, edema, and digestive, respiratory, and renal involvement). Pathological features of patients with pSS with renal involvement are shown in Table 3. In the 12 biopsy patients with pSS with renal involvement, 6 cases had interstitial nephritis and 3 cases had mesangial glomerulonephritis. Three cases had membranous glomerulonephritis, one case diabetic nephropathy, and one case IgA nephropathy.

And the renal damage is shown in Table 4. The prevalence of edema of both lower limbs was higher than 20%. Meanwhile, the occurrences of hypouricuria, frequent micturition, urgency of urine, hematuria, and diuresis were comparatively low.

3.3. Specific Factors Associated with Renal Involvement in pSS Patients. A series of indicators commonly used in clinical practice were selected first by univariate analysis and then logistic regression analysis as potential risk factors for renal involvement in pSS. As is shown in Tables 4 and 5, a series of variables were found to be associated with renal involvement. Compared with pSS patients without renal involvement, edema of both lower limbs and digestive tract involvement were important clinical manifestations \((P < 0.05)\).

### Table 5: Multivariate analysis of factors associated with renal involvement in primary Sjogren’s syndrome.

| Independent variables | Multivariate analysis OR (95% CI) | \(P\) value |
|-----------------------|----------------------------------|-------------|
| Arthralgia            | 1.32 (0.79, 2.22)                | 0.294       |
| Weak                 | 1.83 (1.01, 3.31)                | 0.046       |
| Poor appetite         | 1.52 (0.34, 6.74)                | 0.580       |
| Edema in the face    | 3.33 (0.58, 19.25)               | 0.179       |
| Edema of both lower limbs | 9.16 (3.18, 26.39)             | 0.000       |
| Hypouricinuria       | 1.23 (0.00, 0.01)                | 0.999       |
| Frequent micturition | 2.30 (0.03, 197.13)              | 0.714       |
| Urgency of urine     | 0.51 (0.01, 27.65)               | 0.740       |
| Odynuria             | 1.46 (0.02, 87.33)               | 0.856       |
| Hematuria            | 97021762.92 (0.00)               | 1.000       |
| Polydipsia           | 2521.28 (0.00)                   | 0.999       |
| Diuresis             | 0.00 (0.00)                      | 0.999       |
| Digestive tract symptoms | 3.06 (1.02, 9.22)              | 0.047       |
| Respiratory system symptoms | 0.83 (0.23, 3.01)          | 0.779       |
| Congestion of throat | 9.02 (0.16, 507.78)              | 0.285       |
| Bilateral pleural effusion | 16009499.05 (0.00)        | 0.999       |
| RBC (3.5-5.5×10^{12}/L) | 1.12 (0.70, 1.81)           | 0.637       |
| Hb (110-150 g/L)     | 1.00 (0.99, 1.01)                | 0.831       |
| Urine RBC            | 1.01 (1.00, 1.01)                | 0.015       |
| AST/ALT              | 1.00 (0.68, 1.49)                | 0.987       |
| Prealbumin           | 1.01 (1.00, 1.01)                | 0.026       |
| Total protein (65-85 g/L) | 0.99 (0.95, 1.04)            | 0.778       |
| A/G                  | 1.37 (0.28, 6.68)                | 0.699       |
| Creatinine (44-133 μmol/L) | 1.03 (1.01, 1.04)           | 0.000       |
| Urea nitrogen (2.8-68.2 mmol/L) | 0.97 (0.85, 1.10)           | 0.628       |
| CO₂ CP (22-29 mmol/L) | 0.95 (0.87, 1.03)               | 0.220       |
| Cystatin C (0.1-0.3 mmol/L) | 1.83 (1.16, 2.87)             | 0.009       |
| α₁-MG (10-30 mg/L)   | 1.03 (1.00, 1.05)                | 0.021       |
| Uric acid (90-420 μmol/L) | 1.00 (1.00, 1.00)            | 0.323       |
| β₂-MG (0.97-2.64 mg/L) | 1.01 (0.96, 1.06)              | 0.805       |
| Cl (99-110 mmol/L)   | 1.10 (1.03, 1.12)                | 0.004       |
| Ca (2.08-2.6 mmol/L) | 3.49 (0.47, 25.83)              | 0.221       |
| Apolipoprotein A₁    | 0.56 (0.26, 1.20)                | 0.134       |
| Lipoprotein-α        | 1.00 (0.99, 1.02)                | 0.508       |
| Acid phosphatase (1-9 U/L) | 1.00 (0.91, 1.09)            | 0.916       |
| ESR                  | 1.01 (1.00, 1.02)                | 0.126       |
| Complement-C3 (30.8-82.01 g/L) | 0.46 (0.15, 1.37)         | 0.161       |
| IgM                  | 0.91 (0.71, 1.16)                | 0.434       |
There was a statistical significance in creatinine, cystatin C, α1-MG, and chloridion between pSS patients with and without renal damage.

### 3.4. Comparison of ROC Curves and AUC of Creatinine, Cystatin C, and α1-MG

To compare the significance of multiple indicators (creatinine, cystatin C, and α1-MG) that had significant differences between the two groups in the identification of renal function, we have plotted ROC curves for these biomarkers (Figure 1). For the renal function biomarkers, there was no significant difference in the AUC for biomarkers (cystatin C, index: 0.728, CI 0.699-0.755; α1-MG: 0.775, CI 0.748-0.801; and cystatin C+creatinine: 0.794, CI 0.748-0.801) compared with creatinine. The AUC of combination of creatinine+α1-MG and creatinine+α1-MG+creatinine were statistically larger than those of creatinine, and the biomarker of the biggest AUC is the combination of creatinine+α1-MG (Table 6).

### 4. Discussion

There were 162 patients with renal involvement in this study, and the incidence rate was 16.17% (162/1002). In Goules's study, the prevalence of renal involvement was identified as 4.9% [6]. Another Chinese study also reported a relatively high incidence (33%) of renal abnormalities (based on biochemical abnormalities or kidney biopsy findings) in a study of 524 patients with PSS, 33% [7]. Because of a large number of study subjects in this work, our results suggest that the number of patients and geographical and ethnic factors might contribute to such variability.

PSS is characterized by B-cell activation with high serum IgG levels and a high frequency of autoantibodies [8]. In our study, pSS patients had multiple autoantibodies such as anti-SSA, anti-SSB, and ANA antibody, suggesting that pSS with renal abnormalities may be related to immune dysfunction. However, the pathological features of pSS with renal damage are the lymphocytic infiltration of the renal parenchyma rather than immune complex deposition and renal tubular atrophy that mainly presented interstitial nephritis mediated by an immune mechanism [9–11]. Although investigations about treatments targeting the immune factors participating in the progression of pSS show some positive outcome, more clinical trials were required before their application in human [12].

Among various manifestations of renal involvement, glomerular arterioles may be pathologically changed to glomerulonephritis, and a previous study showed that tubulointerstitial nephritis (TIN) is the most common presentation of renal involvement in the biopsy of pSS, which is consistent with our study [13].

Creatinine is primarily eliminated by glomerular filtration, and it can be used as a convenient means for estimating the glomerular filtration rate. Therefore, measurement of serum creatinine levels is the most common method used clinically for the routine monitoring of renal function [14]. Several studies have shown that serum cystatin C levels were more sensitive for detecting early and mild changes in renal function compared with the sensitivity of serum creatinine levels [15]. Serum cystatin C was produced at a constant rate by all nucleated body cells and was independent of age and gender [16–18]. Cystatin C was freely filtered at the glomerulus and was neither secreted nor reabsorbed by renal tubules [19]. Cystatin can reflect the decline of glomerular filtration rate that was the most direct indicator of renal damage, and it can be used as markers for early renal damage [20, 21]. In our study, the level of cystatin C showed a significant difference between patients with and without renal involvement and was identified as a potential risk factor for renal involvement, which was consistent with another study.

α1-MG was described and isolated from the urine of patients with chronic cadmium poisoning in 1975 [22]. The biochemical characteristics and clinical application value of alpha-1-microglobulin have been studied by scholars. It is synthesized not only by lymphocytes in the human body [2] but also by the liver [23], and it widely exists in various body fluids and on the surface of lymphocytes. α1-MG also is a stable urinary indicator protein which reflects acute and chronic dysfunctions of the proximal renal tubule. Our laboratory examination showed that the level of alpha-1-microglobulin in the pSS with renal damage group was significantly higher than that in the nonrenal damage group, which indicated the damage of proximal renal tubule and subsequent immune response to lymphocyte infiltration of the renal parenchyma in pSS. The combination of creatinine and α1-MG had the best AUC, indicating that the combination of creatinine and α1-MG was more effective in identifying renal function in pSS.

However, limitations of this study should be indicated. Firstly, the limited sample size, as well as bias caused by single-center analysis, should be considered, and secondly, as a cross-sectional study, it is limited to correlation analysis and unable to support strong causal conclusions. Therefore, to further evaluate the role of complement renal complications

| Table 6: AUC of creatinine, cystatin C, and α1-MG. |
|---|---|---|---|
| AUC | 95% CI | P value |
| Creatinine | 0.777 | 0.750-0.803 | >0.05 (vs. creatinine) |
| Cystatin C | 0.728 | 0.699-0.755 | >0.05 (vs. creatinine) |
| α1-Microglobulin | 0.775 | 0.748-0.801 | >0.05 (vs. creatinine) |
| Creatinine+cystatin C | 0.794 | 0.767-0.819 | >0.05 (vs. creatinine) |
| Creatinine+α1-microglobulin | 0.824 | 0.799-0.847 | <0.05 (vs. creatinine) |
| Creatinine+cystatin C + α1-microglobulin | 0.819 | 0.794-0.843 | <0.05 (vs. creatinine) |

AUC: area under the curve; CI: confidence interval.
in SS, more data from heterogeneous SS patients with consecutive follow-up are highly recommended.

5. Conclusions
Renal involvement is common in pSS patients. The combination of creatinine and $\alpha_1$-MG is a better indicator of renal function for pSS patients, and close attention should be paid to it in clinical practice.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work. There is no professional or other personal interest of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in, or the review of, the manuscript.

Authors’ Contributions
Jing Luo and Yu-Wei Huo contributed equally to this work.

Acknowledgments
This study was supported by the Preferential Financed Projects of Shanxi Provincial Human Resources and Social Security Department (2016-97), the Scientific Research Project of Shanxi Health Planning Committee (201601042), the Scientific Research Project of Shenzhen University General Hospital (0000040522), and the Scientific Research Foundation for the Returned Overseas Scholar of Shanxi Province (2017-116).

References
[1] H. Murata, Y. Kita, A. Sakamato et al., “Limited TCR repertoire of infiltrating T cells in the kidneys of Sjögren’s syndrome patients with interstitial nephritis,” The Journal of Immunology, vol. 155, no. 8, pp. 4084–4089, 1995.
[2] Y. Itoh, K. Kin, T. Kasahara et al., “Synthesis and secretion of alpha 1-microglobulin by human lymphocytes,” Clinical & Experimental Immunology, vol. 37, no. 1, pp. 134–139, 1979.
[3] M. Jallouli, M. Frigui, S. Marzouk et al., “Osteomalacia revealing Sjögren’s syndrome: a case report,” La Revue de Médecine Interne, vol. 29, no. 4, pp. 311–314, 2008.
[4] C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554–558, 2002.
[5] C. M. Laing and R. J. Unwin, “Renal tubular acidosis,” Journal of Nephrology, vol. 19, pp. 46–52, 2006.
[6] A. V. Goules, I. P. Tatoulis, H. M. Moutsopoulos, and A. G. Tzioufas, “Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome,” Arthritis and Rheumatism, vol. 65, no. 11, pp. 2945–2953, 2013.
[7] D. F. Lin, S. M. Yan, Y. Zhao et al., “Clinical and prognostic characteristics of 573 cases of primary Sjögren’s syndrome,” Chinese Medical Journal, vol. 123, no. 22, pp. 3252–3257, 2010.
[8] M. García-Carrasco, M. Ramos-Casals, J. Rosas et al., “Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients,” Medicine, vol. 81, no. 4, pp. 270–280, 2002.
[9] R. L. Winzen, “Sjögren’s syndrome. Renal involvement in multisystem disease,” Textbook of Nephrology, S. G. Massry and G. R. J. Eda, Eds., pp. 823–827, 1995.
[10] T. Both, E. J. Hoorn, R. Zietse et al., “Prevalence of distal renal tubular acidosis in primary Sjögren’s syndrome,” Rheumatology, vol. 54, no. 5, pp. 933–939, 2015.
[11] S. Maripuri, J. P. Grande, T. G. Osborn et al., “Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1423–1431, 2009.
[12] Y.-f. Huang, Q. Cheng, C. M. Jiang et al., “The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjögren’s syndrome,” Clinical and Developmental Immunology, vol. 2013, Article ID 160491, 6 pages, 2013.
[13] S. Maripuri, J. P. Grande, T. G. Osborn et al., “Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 9, pp. 1423–1431, 2009.
[14] E.-I. Lepist, X. Zhang, J. Hao et al., “Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat,” Kidney International, vol. 86, no. 2, pp. 350–357, 2014.
[15] F. J. Hoek, F. A. W. Kemperman, and R. T. Krediet, “A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate,” Nephrol. Dialysis, Transplantation, vol. 18, no. 10, pp. 2024–2031, 2003.
[16] G. Filler and N. Lepage, “Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula?” Pediatric Nephrology, vol. 18, no. 10, pp. 981–985, 2003.
[17] V. F. Cordeiro, D. C. S. N. Pinheiro, G. B. Silva Jr et al., “Comparative study of cystatin C and serum creatinine in the estimative of glomerular filtration rate in children,” Clinica Chimica Acta, vol. 391, no. 1-2, pp. 46–50, 2008.
[18] A. Ramel, P. V. Jonsson, S. Bjornsson, and I. Thorsdottir, “Differences in the glomerular filtration rate calculated by two creatinine-based and three cystatin-C-based formulae in hospitalized elderly patients,” Nephron Clinical Practice, vol. 108, no. 1, pp. c16–c22, 2008.
[19] O. Tenstad, A. B. Roald, A. Grubb, and K. Aukland, “Renal handling of radiolabelled human cystatin C in the rat,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 56, no. 5, pp. 409–414, 1996.
[20] C. A. Gökküsu, T. A. Özden, H. Gül, and A. Yıldız, “Relationship between plasma cystatin C and creatinine in chronic renal diseases and Tx-transplant patients,” Clinical Biochemistry, vol. 37, no. 2, pp. 94–97, 2004.
[21] V. R. Dharmidharka, C. Kwon, and G. Stevens, “Serum cystatin C is superior to serum creatinine as a marker of kidney
function: a meta-analysis,” *American Journal of Kidney Diseases*, vol. 40, no. 2, pp. 221–226, 2002.

[22] B. Ekstrom and I. Berggard, “Human α1-microglobulin. Purification procedure, chemical and physicochemical properties,” *The Journal of Biological Chemistry*, vol. 252, pp. 8048–8057, 1997.

[23] C. Vincent, M. Marceau, P. Blangarin, P. Bouic, J.-J. Madjar, and J.-P. Revillard, “Purification of α1-microglobulin produced by human hepatoma cell lines: biochemical characterization and comparison with α1-microglobulin synthesized by human hepatocytes,” *European Journal of Biochemistry*, vol. 165, no. 3, pp. 699–704, 1987.